EMAIL THIS PAGE TO A FRIEND

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

A GCase chaperone improves motor function in a mouse model of synucleinopathy.


PMID 25037721

Abstract

Mutation of the lysosomal hydrolase acid-β-glucosidase (GCase), which leads to reduced GCase activity, is one of the most frequent genetic risk factors for Parkinson's disease (PD) and promotes α-synuclein accumulation in the brain, a hallmark of PD and other synucleinopathies. Whether targeting GCase pharmacologically is a valid therapeutic strategy for sporadic PD in the absence of GCase mutation is unknown. We have investigated whether increasing the stability, trafficking, and activity of wild-type GCase could be beneficial in synucleinopathies by administering the pharmacological chaperone AT2101 (afegostat-tartrate, isofagomine) to mice that overexpress human wild-type α-synuclein (Thy1-aSyn mice). AT2101 administered orally for 4 months to Thy1-aSyn mice improved motor and nonmotor function, abolished microglial inflammatory response in the substantia nigra, reduced α-synuclein immunoreactivity in nigral dopaminergic neurons, and reduced the number of small α-synuclein aggregates, while increasing the number of large α-synuclein aggregates. These data support the further investigation of pharmacological chaperones that target GCase as a therapeutic approach for sporadic PD and other synucleinopathies, even in the absence of glucocerebrosidase mutations.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

HPA049234
Anti-AIF1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1405854
Anti-GBA antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA006667
Anti-GBA antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1410509
Anti-GBA antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
G4171
Anti-Glucocerebrosidase (C-terminal) antibody produced in rabbit, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution
G4046
Anti-Glucocerebrosidase antibody produced in rabbit, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution
SAB2103892
Anti-TH, (N-terminal) antibody produced in rabbit, affinity isolated antibody
SAB2103911
Anti-TH, (N-terminal) antibody produced in rabbit, affinity isolated antibody
T8700 Anti-Tyrosine Hydroxylase antibody produced in rabbit, affinity isolated antibody, buffered aqueous glycerol solution, sufficient for 10 blots
WH0002629M1
Monoclonal Anti-GBA antibody produced in mouse, clone 2e2, purified immunoglobulin, buffered aqueous solution
SAB1403853
Monoclonal Anti-GBA antibody produced in mouse, clone 2H4, purified immunoglobulin, buffered aqueous solution